Comparison of immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) assessment for Her-2 status in breast cancer

World Journal of Surgical Oncology

Volumn 7, Issue , 2009, Pages 83-

  Sui, Weiguo ^a   Ou, Minglin ^a,b   Chen, Jiejing ^a   Wan, Youhua ^a   Peng, Hongbo ^a   Qi, Minfang ^a   Huang, He ^a   Dai, Yong ^a  

^a The 181th Hospital of PLA   (China)

^b GUANGXI NORMAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2;

ARTICLE; BREAST CANCER; CONTROLLED STUDY; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTERMETHOD COMPARISON; INTRADUCTAL CARCINOMA; KAPPA STATISTICS; PROSPECTIVE STUDY; PROTEIN ANALYSIS; PROTEIN EXPRESSION;

BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CHINA; FEMALE; GENE AMPLIFICATION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, ERBB-2; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; RECEPTOR, ERBB-2; REPRODUCIBILITY OF RESULTS; TISSUE FIXATION;

EID: 70749108747     PISSN: None     EISSN: 14777819     Source Type: Journal    
DOI: 10.1186/1477-7819-7-83     Document Type: Article

References (23)

1. Parkin DM, Bray F, Ferlay J. Global cancer statistics, 2002. CA Cancer J Clin 2005, 55(2):74-108. 10.3322/canjclin.55.2.74, 15761078.
2. Zheng Y, Li DL, Xiang YM, Li XJ. The status and trend of breast cancer incidence in Shanghai. J Surg Concepts Pract 2001, 6:219-221.
3. Paterson MC, Dietrich KD, Danyluk J, Paterson AH, Lees AW, Jamil N, Hanson J, Jenkins H, Krause BE, McBlain WA. Correlation between c-erbB-2 amplification and risk of recurrent disease in node-negative breast cancer. Cancer Res 1991, 51(2):556-67.
4. Seshadri R, Firgaira FA, Horsfall DJ, McCaul K, Setlur V, Kitchen P. Clinical significance of HER-2/neu oncogene amplification in primary breast cancer. The South Australian Breast Cancer Study Group. J Clin Oncol 1993, 11(10):1936-42.
5. Press MF, Pike MC, Chazin VR, Hung G, Udove JA, Markowicz M, Danyluk J, Godolphin W, Sliwkowski M, Akita R. Her-2/neu expression in node-negative breast cancer: direct tissue quantitation by computerized image analysis and association of overexpression with increased risk of recurrent disease. Cancer Res 1993, 53(20):4960-70.
6. Press MF, Bernstein L, Thomas PA, Meisner LF, Zhou JY, Ma Y, Hung G, Robinson RA, Harris C, El-Naggar A, Slamon DJ, Phillips RN, Ross JS, Wolman SR, Flom KJ. HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas. J Clin Oncol 1997, 15(8):2894-904.
7. Ross JS, Fletcher JA. The HER-2/neu oncogene: prognostic factor, predictive factor and target for therapy. Semin Cancer Biol 1999, 9(2):125-38. 10.1006/scbi.1998.0083, 10202134.
8. Dean-Colomb W, Esteva FJ. Her2-positive breast cancer: herceptin and beyond. Eur J Cancer 2008, 44(18):2806-12. 10.1016/j.ejca.2008.09.013, 19022660.
9. Tanner M, Gancberg D, Di Leo A, Larsimont D, Rouas G, Piccart MJ, Isola J. Chromogenic in situ hybridization: a practical alternative for fluorescence in situ hybridization to detect HER-2/neu oncogene amplification in archival breast cancer samples. Am J Pathol 2000, 157(5):1467-72. 1885742, 11073807.
10. Sáez A, Andreu FJ, Seguí MA, Baré ML, Fernández S, Dinarés C, Rey M. HER-2 gene amplification by chromogenic in situ hybridisation (CISH) compared with fluorescence in situ hybridisation (FISH) in breast cancer-A study of two hundred cases. Breast 2006, 15(4):519-27. 10.1016/j.breast.2005.09.008, 16290155.
11. Reed W, Hannisdal E, Boehler PJ, Gundersen S, Host H, Nesland JM. The prognostic value of p53 and c-erb B-2 immunostaining is overrated for patients with lymph node negative breast carcinoma: a multivariate analysis of prognostic factors in 613 patients with a follow-up of 14-30 years. Cancer 2000, 88(4):804-13. 10.1002/(SICI)1097-0142(20000215)88:4<804::AID-CNCR11>3.0.CO;2-Y, 10679650.
12. Pauletti G, Dandekar S, Rong H, Ramos L, Peng H, Seshadri R, Slamon DJ. Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: a direct comparison of fluorescence in situ hybridization and immunohistochemistry. J Clin Oncol 2000, 18(21):3651-64.
13. Tubbs RR, Pettay JD, Roche PC, Stoler MH, Jenkins RB, Grogan TM. Discrepancies in clinical laboratory testing of eligibility for trastuzumab therapy: apparent immunohistochemical false-positives do not get the message. J Clin Oncol 2001, 19(10):2714-21.
14. Wolff AC, Hammond EH, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, Dowsett M, Fitzgibbons PL, Hanna WM, Langer A, McShane LM, Paik S, Pegram MD, Perez EA, Press MF, Rhodes A, Sturgeon C, Taube SE, Tubbs R, Vance GH, Vijver M, Wheeler TM, Hayes DF. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 2007, 25(1):118-45. 10.1200/JCO.2006.09.2775, 17159189.
15. Dolan M, Snover D. Comparison of immunohistochemical and fluorescence in situ hybridization assessment of HER-2 status in routine practice. Am J Clin Pathol 2005, 123(5):766-70. 10.1309/Q0DGL26RUCK1K5EV, 15981817.
16. Keefe DL. Trastuzumab-associated cardiotoxicity. Cancer 2002, 95(7):1592-600. 10.1002/cncr.10854, 12237930.
17. Bempt I, Vanhentenrijk V, Drijkoningen M, Vandenberghe P, De WC. Real-time reverse transcription-PCR and fluorescence in-situ hybridization are complementary to understand the mechanisms involved in HER-2/neu overexpression in human breast carcinomas. Histopathology 2005, 46(4):431-41. 10.1111/j.1365-2559.2005.02112.x, 15810955.
18. Owens MA, Horten BC, Da Silva MM. HER2 amplification ratios by fluorescence in situ hybridization and correlation with immunohistochemistry in a cohort of 6556 breast cancer tissues. Clin Breast Cancer 2004, 5(1):63-9. 10.3816/CBC.2004.n.011, 15140287.
19. Dybdal N, Leiberman G, Anderson S. Determination of HER2 gene amplification by fluorescence in situ hybridization and concordance with the clinical trials immunohistochemical assay in women with metastatic breast cancer evaluated for treatment with trastuzumab. Breast Cancer Res Treat 2005, 93(1):3-11. 10.1007/s10549-004-6275-8, 16184453.
20. Mass RD, Press MF, Anderson S, Cobleigh MA, Vogel CL, Dybdal N, Leiberman G, Slamon DJ. Evaluation of clinical outcomes according to HER2 detection by fluorescence in situ hybridization in women with metastatic breast cancer treated with trastuzumab. Clin Breast Cancer 2005, 6(3):240-6. 10.3816/CBC.2005.n.026, 16137435.
21. Lan C, Liu JM, Liu TW, Hsu D, Liang S, Chen JR, Peng JW. Erb-b2 amplification by fluorescence in situ hybridization in breast cancer specimens read as 2+ in immunohistochemical analysis. Am J Clin Pathol 2005, 124(1):97-102. 10.1309/R2X4KK22QCL7PLME, 15923160.
22. Kuo SJ, Wang BB, Chang CS, Chen TH, Yeh KT, Lee DJ, Yin PL, Chen M. Comparison of immunohistochemical and fluorescence in situ hybridization assessment for HER-2/neu status in Taiwanese breast cancer patients. Taiwan J Obstet Gynecol 2007, 46(2):146-51. 10.1016/S1028-4559(07)60008-4, 17638622.
23. Jacobs TW, Gown AM, Yaziji H, Barnes MJ, Schnitt SJ. HER-2/neu protein expression in breast cancer evaluated by immunohistochemistry. A study of interlaboratory agreement. Am J Clin Pathol 2000, 113(2):251-8. 10.1309/980M-E24R-V19K-595D, 10664627.